We are live on ! Find out more
SL

Siren LLC Portfolio holdings

AUM $4.94B
1-Year Est. Return 244.43%
This Fund
S&P 500
This Quarter Est. Return
+34.74%
1 Year Est. Return
+244.43%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.94B
AUM Growth
+$1.33B
Cap. Flow
+$314M
Cap. Flow %
6.35%
Top 10 Hldgs %
44.63%
Holding
126
New
26
Increased
32
Reduced
21
Closed
9

Top Buys

Rank Stock Value
1
PBLS
Parabilis Medicines Inc
PBLS
+$82.7M
2
ABVX
Abivax
ABVX
+$65.2M
3
COAG
Hemab Therapeutics
COAG
+$57.6M
4
RLAY icon
Relay Therapeutics
RLAY
+$53M
5
KLRA
Kailera Therapeutics
KLRA
+$48.7M

Top Sells

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$60.4M
2
EWTX icon
Edgewise Therapeutics
EWTX
+$42.9M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$41.8M
4
RVMD icon
Revolution Medicines
RVMD
+$30.8M
5
KYMR icon
Kymera Therapeutics
KYMR
+$21.6M

Sector Composition

Rank Sector Weight
1 Healthcare 92.94%
2 Technology 3.57%
3 Communication Services 1.85%
4 Financials 0.87%
5 Consumer Discretionary 0.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORKA
51
Oruka Therapeutics
ORKA
$6.47B
$23.8M 0.48%
+250,000
New +$16.7M
SPTX
52
Seaport Therapeutics
SPTX
$1.18B
$23.8M 0.48%
+1,095,316
New +$19.3M
DMRA
53
Damora Therapeutics
DMRA
$1.41B
$23.4M 0.47%
900,000
– –
TYRA icon
54
Tyra Biosciences
TYRA
$1.68B
$23.2M 0.47%
+725,000
New +$24M
ZURA icon
55
Zura Bio
ZURA
$436M
$22M 0.45%
3,734,866
– –
TSM icon
56
TSMC
TSM
$2.23T
$21.3M 0.43%
44,700
+2,500
+6% +$1.01M
NVDA icon
57
NVIDIA
NVDA
$5.3T
$19M 0.38%
95,000
+5,915
+7% +$1.22M
RZLT icon
58
Rezolute
RZLT
$379M
$17.3M 0.35%
3,328,287
– –
MPLT
59
MapLight Therapeutics
MPLT
$528M
$16.1M 0.33%
450,000
– –
NMRA icon
60
Neumora Therapeutics
NMRA
$140M
$14.4M 0.29%
8,497,822
– –
NBIS
61
Nebius Group N.V.
NBIS
$59.2B
$14.4M 0.29%
52,000
-61,614
-54% -$12.2M
MSFT icon
62
Microsoft
MSFT
$3.7T
$14M 0.28%
37,500
-3,880
-9% -$1.57M
CTMX icon
63
CytomX Therapeutics
CTMX
$617M
$13M 0.26%
3,457,711
– –
GENB
64
Generate Biomedicines
GENB
$2.21B
$12.4M 0.25%
736,104
– –
IKT icon
65
Inhibikase Therapeutics
IKT
$320M
$11.9M 0.24%
5,850,000
– –
ADAG
66
Adagene
ADAG
$225M
$11.2M 0.23%
+2,666,666
New +$10M
ENGN icon
67
enGene Therapeutics
ENGN
$128M
$10.8M 0.22%
6,256,662
+1,003,503
+19% +$4.09M
WHWK
68
Whitehawk Therapeutics
WHWK
$234M
$10.7M 0.22%
2,337,102
+255,102
+12% +$1.06M
DDOG icon
69
Datadog
DDOG
$85B
$10.4M 0.21%
40,000
-14,300
-26% -$2.66M
NOW icon
70
ServiceNow
NOW
$143B
$9.93M 0.2%
100,000
+12,910
+15% +$1.28M
AVGO icon
71
Broadcom
AVGO
$1.66T
$9.44M 0.19%
25,000
+10,000
+67% +$4.01M
IONQ icon
72
IonQ
IONQ
$16.4B
$9.05M 0.18%
170,000
– –
MSFT icon
73
CALL
Microsoft
MSFT
$3.7T
$8.95M 0.18%
+24,000
New +$9.71M
FROG icon
74
JFrog
FROG
$11.6B
$8.68M 0.18%
95,500
-33,316
-26% -$2.16M
OCS icon
75
Oculis Holding
OCS
$553M
$8.67M 0.18%
+625,000
New +$14.2M
1 2
3
4 5

Similar funds

AAS
Ameritas Advisory Services Lincoln, Nebraska $4.96B AUM 27.52% 1-Year Est. Return
B
Bailard Foster City, California $4.91B AUM 31.75% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
FC
Freemont Capital Singapore $4.9B AUM 11.61% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $4.99B AUM 23.08% 1-Year Est. Return
CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $5B AUM 26.58% 1-Year Est. Return

Siren LLC's Q2 2026 Portfolio in Review

As of Q2 2026, Siren LLC held 126 positions worth $4.94B, up 37% from $3.61B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Siren LLC deployed $314M of net new capital in Q2 2026, opening 26 new positions and adding to 32 existing holdings. Its largest new stake was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Scholar Rock, an estimated $60.4M trimmed.

  • Siren LLC's largest Q2 2026 buy was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.
  • Siren LLC added most to Enliven Therapeutics in Q2 2026, an estimated $43.7M increase.
  • Siren LLC's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $60.4M.
  • Siren LLC fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $41.8M.
  • Siren LLC's ten largest holdings make up 45% of its $4.94B portfolio in Q2 2026.
  • Siren LLC opened 26 new positions and closed 9 in Q2 2026.
  • Siren LLC's portfolio value rose 37% quarter-over-quarter to $4.94B.

Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.